Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 13/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7260329 | 1.00 | HTR4 (0.61) | HTR4CYP1A2CYP3A4ADRA2ACYP2D6 | |
| SCHEMBL7261606 | 1.00 | HTR4 (0.61) | HTR4CYP1A2CYP3A4ADRA2ACYP2D6 | |
| Fumaric Acid SCHEMBL7264897 | 0.96 | HTR4 (0.56) | HTR4CYP1A2CYP3A4ADRA2ACYP2D6 | |
| Fumaric Acid SCHEMBL6580490 | 0.96 | HTR4 (0.56) | HTR4CYP1A2CYP3A4ADRA2ACYP2D6 | |
| Maleic Acid SCHEMBL7260321 | 0.96 | HTR4 (0.56) | HTR4CYP1A2CYP3A4ADRA2ACYP2D6 | |
| SCHEMBL6583375 | 0.87 | HTR4 (0.64) | HTR4CYP1A2CYP3A4ADRA2ACYP2D6 | |
| SCHEMBL6583145 | 0.87 | HTR4 (0.73) | HTR4CYP1A2CYP3A4ADRA2ACYP2D6 | |
| SCHEMBL6586524 | 0.86 | HTR4 (0.71) | HTR4CYP1A2CYP3A4ADRA2ACYP2D6 | |
| SCHEMBL6580662 | 0.86 | HTR4 (0.61) | HTR4CYP1A2CYP3A4ADRA2ACYP2D6 | |
| SCHEMBL6774576 | 0.85 | HTR4 (0.62) | HTR4CYP1A2CYP3A4ADRA2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1362857-B1 | (S)-4-amino-5-chloro-2-methoxy-N-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide for treating gastrointestinal motility disorders | DAINIPPON PHARMACEUTICAL CO (JP) | 2004-08-11 | — | — | EP | claimed |
| WO-2003097638-A1 | (S)-4-AMINO-5-CHLORO-2-METHOXY-N-[1-[1-(2-TETRAHYDROFURYLCARBONYL)-4-PIPERIDINYLMETHYL]-4-PIPERIDINYL]BENZAMIDE, PROCESS FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND INTERMEDIATE THEREFOR | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2003-11-27 | — | — | WO | claimed |
| US-20030216433-A1 | (S)-4-amino-5-chloro-2-methoxy-N-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2003-11-20 | — | — | US | claimed |
| EP-1362857-A1 | (S)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinymethyl]-4-piperidinyl]benzamide for treating gastrointestinal motility disorders | Dainippon Pharmaceutical Co., Ltd. (JP) | 2003-11-19 | — | — | EP | claimed |
| CN-1653063-A | (S)-4-amino-5-chloro-2-methoxy-N-[1-[1-(2-tetrahydrofurylcarbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, and method for producing the same, pharmaceutical composition containing the same and i | DAINIPPON PHARMACEUTICAL CO (JP) | 2005-08-10 | — | — | CN | disclosed |
| CN-1653063-A | (S)-4-amino-5-chloro-2-methoxy-N-[1-[1-(2-tetrahydrofurylcarbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, and method for producing the same, pharmaceutical composition containing the same and i | DAINIPPON PHARMACEUTICAL CO (JP) | 2005-08-10 | — | — | CN | disclosed |
| JP-2005170933-A | PHARMACEUTICAL COMPRISING (S)-4-AMINO-5-CHLORO-2-METHOXY-N-[1-[1-(2-TETRAHYDROFURYLCARBONYL)-4-PIPERIDINYLMETHYL]-4-PIPERIDINYL]BENZAMIDE | DAINIPPON PHARMACEUT CO LTD | 2005-06-30 | — | — | JP | disclosed |
| JP-2005170933-A | PHARMACEUTICAL COMPRISING (S)-4-AMINO-5-CHLORO-2-METHOXY-N-[1-[1-(2-TETRAHYDROFURYLCARBONYL)-4-PIPERIDINYLMETHYL]-4-PIPERIDINYL]BENZAMIDE | DAINIPPON PHARMACEUT CO LTD | 2005-06-30 | — | — | JP | disclosed |
| EP-1362857-B1 | (S)-4-amino-5-chloro-2-methoxy-N-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide for treating gastrointestinal motility disorders | DAINIPPON PHARMACEUTICAL CO (JP) | 2004-08-11 | — | — | EP | disclosed |
| EP-1362857-B1 | (S)-4-amino-5-chloro-2-methoxy-N-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide for treating gastrointestinal motility disorders | DAINIPPON PHARMACEUTICAL CO (JP) | 2004-08-11 | — | — | EP | disclosed |
| US-6696468-B2 | GASTROINTESTINAL MOTILITY ENHANCER OR PROKINETIC AGENT; AFFINITY FOR 5-HT4 RECEPTOR; REDUCED SIDE EFFECTS TO HEART OR CENTRAL NERVOUS SYSTEM | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-02-24 | — | — | US | disclosed |
| US-6696468-B2 | GASTROINTESTINAL MOTILITY ENHANCER OR PROKINETIC AGENT; AFFINITY FOR 5-HT4 RECEPTOR; REDUCED SIDE EFFECTS TO HEART OR CENTRAL NERVOUS SYSTEM | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-02-24 | — | — | US | disclosed |
| JP-2004043453-A | (S)-4-AMINO-5-CHLORO-2-METHOXY-N-[1-[1-(2-TETRAHYDROFURYLCARBONYL)-4-PIPERIDINYLMETHYL]-4-PIPERIDINYL]BENZAMIDE, AND METHOD FOR PRODUCING THE SAME, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AND INTERMEDIATE OF THE COMPOUND | DAINIPPON PHARMACEUT CO LTD | 2004-02-12 | — | — | JP | disclosed |
| WO-2003097638-A1 | (S)-4-AMINO-5-CHLORO-2-METHOXY-N-[1-[1-(2-TETRAHYDROFURYLCARBONYL)-4-PIPERIDINYLMETHYL]-4-PIPERIDINYL]BENZAMIDE, PROCESS FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND INTERMEDIATE THEREFOR | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003097638-A1 | (S)-4-AMINO-5-CHLORO-2-METHOXY-N-[1-[1-(2-TETRAHYDROFURYLCARBONYL)-4-PIPERIDINYLMETHYL]-4-PIPERIDINYL]BENZAMIDE, PROCESS FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND INTERMEDIATE THEREFOR | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003097638-A1 | (S)-4-AMINO-5-CHLORO-2-METHOXY-N-[1-[1-(2-TETRAHYDROFURYLCARBONYL)-4-PIPERIDINYLMETHYL]-4-PIPERIDINYL]BENZAMIDE, PROCESS FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND INTERMEDIATE THEREFOR | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2003-11-27 | — | — | WO | disclosed |
| US-20030216433-A1 | (S)-4-amino-5-chloro-2-methoxy-N-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2003-11-20 | — | — | US | disclosed |
| US-20030216433-A1 | (S)-4-amino-5-chloro-2-methoxy-N-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2003-11-20 | — | — | US | disclosed |
| EP-1362857-A1 | (S)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinymethyl]-4-piperidinyl]benzamide for treating gastrointestinal motility disorders | Dainippon Pharmaceutical Co., Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
| EP-1362857-A1 | (S)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinymethyl]-4-piperidinyl]benzamide for treating gastrointestinal motility disorders | Dainippon Pharmaceutical Co., Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216433-A1 | (S)-4-amino-5-chloro-2-methoxy-N-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor | GIPR, MLNR, HTR5A | HTR4 4/4885CYP1A2 1125/4885CYP3A4 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.